In Enlightenment philosophy, this notion was secularized as a bifurcated sense of physical and mental life often tagged “Cartesian dualism,” in reference to its iconic articulator, 17th century French ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price target remains the same with $42.00. Julian Harrison has ...

Cartesian Therapeutics, Inc. announced that it received FDA agreement on the design of its upcoming Phase 3 AURORA trial for Descartes-08, an mRNA cell therapy intended for treating myasthenia ...

About Descartes-08 Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product targeting B-cell ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics ... design of the Company’s planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate, in myasthenia gravis ...